Photosensitive dermatitis due to sunscreen allergy in a child

We report a case of photoallergic contact dermatitis to two sunscreen agents, methoxycinnamate and oxybenzone, occurring in a 6-year-old Asian boy.     

Pain coping profiles in adolescents with chronic pain

This study sought to evaluate the extent to which the pain coping profiles observed by Walker and colleagues in a sample of patients with chronic abdominal pain also were evident in a sample of adolescent patients who presented to a tertiary care clinic for evaluation of a variety of diverse pain conditions. In addition, we aimed to evaluate the relation of these pain coping profiles to patients' emotional and physical functioning. Participants (n=254) were adolescent patients aged 12-17 years. Patients completed the Pain Response Inventory (PRI) as well as measures of pain, somatic symptoms, anxiety and depressive symptoms, and functional disability. Using the PRI classification algorithm developed by Walker and colleagues, we successfully classified all the patients in our sample. We also found that the pain coping profiles successfully differentiated among patients with different levels of symptoms, disability, and emotional distress, further demonstrating the external validity of these profiles. Results have implications for tailoring pain treatment interventions to patients' particular coping profiles.     

MIDAS and HIT-6 French translation: reliability and correlation between tests

The aim was to evaluate the test-retest reliability of the French translation of the Migraine Disability Assessment (MIDAS) and Headache Impact Test (HIT)-6 questionnaires as applied to episodic and chronic headaches and to assess the correlation between these two questionnaires. The MIDAS and HIT-6 questionnaires, which assess the degree of migraine-related functional disability, are widely used in headache treatment clinics. The French translation has not been checked for test-retest reliability. MIDAS involves recall, over the previous 3 months, of the number of days with functional disability with regard to work and to home and social life. HIT-6 involves a more subjective and general assessment of headache-related disability over the previous 4 weeks. We expect that there may be greater impact recall bias for chronic headaches than for episodic headaches and considered it important to be able to determine if the reliability of these questionnaires is equally good for these two patient populations. Given that both questionnaires have the same objective, that of assessing headache impact, it was thought useful to determine if their results might show a correlation and if they could thus be used interchangeably. The study was approved by an external ethics committee. The subjects were patients who regularly visit the Clinique de la Migraine de Montréal, which specializes in the treatment of headaches. The MIDAS and HIT-6 questionnaires were completed by the patients during their regular visit. Twelve days later, the same questionnaires were mailed with a prepaid return envelope. Sixty-five patients were required in both the episodic and chronic headache groups, assuming an 80% questionnaire return rate. One hundred and eighty-five patients were enrolled, and 143 completed the study, 75 with episodic headaches and 68 with chronic headaches. The questionnaire return rate was 78.9%. On average, questionnaires were completed a second time 21 days after the first, with a median of 19 days. The Shrout-Fleiss intraclass correlation coefficients for MIDAS and HIT-6 were, respectively, 0.76 and 0.77 for episodic headaches and 0.83 and 0.80 for chronic headaches. The Pearson correlation coefficient between the MIDAS and HIT-6 questionnaires was 0.48 for episodic headaches and 0.58 for chronic headaches at the first compilation and 0.42 and 0.59 at the second compilation. The test-retest intraclass correlation of the French versions for both MIDAS and HIT-6 questionnaires indicates moderate reliability for episodic headache and substantial reliability for chronic headache. The correlation between the MIDAS and HIT-6 questionnaires is weak for episodic headaches, but approaches a level of 'good' for chronic headaches.     

BNP-mediated vasodilatation for dialysis-dependent patient with acute heart failure syndrome in the emergency department

Acutely decompensated heart failure syndrome is a common emergency department presentation in patients with renal failure. B-type natriuretic peptide-mediated vasodilatation may provide a unique bridge in renal failure patients with acutely decompensated heart failure syndrome to treatment with dialysis. We evaluated the efficacy of B-type natriuretic peptide-mediated vasodilatation in acutely decompensated heart failure syndrome emergency department patients with hemodialysis dependent renal failure. This was a prospective, interventional trial. All patients received nesiritide infusion in addition to usual care. Outcome measures included hemodynamic parameters and dyspnea visual analog scale. Eight patients were enrolled, and all demonstrated significant improvement in their dyspnea visual analog scale (Delta 50.1 mm; p < .001 vs. pre-infusion) and APEX score (Delta 48.4%; p < .001 vs. pre-infusion). Three patients improved enough to be discharged from the emergency department for outpatient dialysis. In this hypothesis-generating initial trial, B-type natriuretic peptide-mediated vasodilatation with nesiritide improved symptoms in heart failure patients with hemodialysis-dependent renal failure and appears additive to standard treatment. Further trials are required to test this hypothesis.